6OD Stock Overview
ODI Pharma AB (publ), a pharmaceutical company, produces and distributes pharmaceutical cannabis and cosmetics products in Europe.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ODI Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.61 |
| 52 Week High | kr0.62 |
| 52 Week Low | kr0.22 |
| Beta | 0.52 |
| 1 Month Change | 57.69% |
| 3 Month Change | 64.44% |
| 1 Year Change | 71.79% |
| 3 Year Change | 28.13% |
| 5 Year Change | n/a |
| Change since IPO | 31.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6OD | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.5% | 2.6% | 1.9% |
| 1Y | 71.8% | -22.6% | 5.9% |
Return vs Industry: 6OD exceeded the German Pharmaceuticals industry which returned -22.6% over the past year.
Return vs Market: 6OD exceeded the German Market which returned 5.9% over the past year.
Price Volatility
| 6OD volatility | |
|---|---|
| 6OD Average Weekly Movement | 10.9% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6OD's share price has been volatile over the past 3 months.
Volatility Over Time: 6OD's weekly volatility has decreased from 22% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 1 | Derek Simmross | www.odipharma.com |
ODI Pharma AB (publ), a pharmaceutical company, produces and distributes pharmaceutical cannabis and cosmetics products in Europe. The company offers cannabidiol-infused facial cream, facial mask, and body balm under the Kandol. brand name through kandol.net.
ODI Pharma AB (publ) Fundamentals Summary
| 6OD fundamental statistics | |
|---|---|
| Market cap | €10.02m |
| Earnings (TTM) | -€339.41k |
| Revenue (TTM) | €69.99k |
143.2x
P/S Ratio-29.5x
P/E RatioIs 6OD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6OD income statement (TTM) | |
|---|---|
| Revenue | kr818.38k |
| Cost of Revenue | kr1.25m |
| Gross Profit | -kr434.28k |
| Other Expenses | kr3.53m |
| Earnings | -kr3.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | -0.26 |
| Gross Margin | -53.07% |
| Net Profit Margin | -484.96% |
| Debt/Equity Ratio | 0% |
How did 6OD perform over the long term?
See historical performance and comparison